EPHA5 and lung adenocarcinoma: A couple of studies showed that the lung adenocarcinoma patients with EPHA5 mutations from a Memorial Sloan-Kettering Cancer Center (MSKCC) cohort treated with immunotherapy exhibited significantly prolonged overall survival (OS) times, indicating that EPHA5 mutation might serve as a biomarker to predict the immune response of lung adenocarcinomas [11, 12].